EQL Pharma AB (publ) announced Christer Fåhraeus, Founder & CEO, notified the board in the autumn of 2021 that he intends to transition into a board position after the Annual General Meeting (AGM) in August 2022. At that time, the board appointed Axel Schörling, Deputy CEO, as new CEO after Fåhraeus' resignation following the AGM in August 2022. After AGM, Schörling has assumed the position as new CEO in EQL.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
52.6 SEK | +5.20% | +11.44% | +57.49% |
05-15 | Transcript : EQL Pharma AB, Q4 2024 Earnings Call, May 15, 2024 | |
05-14 | EQL Pharma AB Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.49% | 145M | |
-37.88% | 13.99B | |
-33.12% | 10.67B | |
+12.54% | 6.29B | |
-11.17% | 5.88B | |
+75.00% | 4.93B | |
-4.38% | 4.54B | |
-9.20% | 3.74B | |
-19.40% | 3.16B | |
-12.15% | 2.85B |
- Stock Market
- Equities
- EQL Stock
- News EQL Pharma AB
- Eql Pharma AB Announces Executive Changes